Wuxi Biologics Stock Total Debt
| WXXWY Stock | USD 3.76 0.01 0.27% |
WuXi Biologics fundamentals help investors to digest information that contributes to WuXi Biologics' financial success or failures. It also enables traders to predict the movement of WuXi Pink Sheet. The fundamental analysis module provides a way to measure WuXi Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to WuXi Biologics pink sheet.
WuXi |
WuXi Biologics Company Total Debt Analysis
WuXi Biologics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current WuXi Biologics Total Debt | 640.51 M |
Most of WuXi Biologics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, WuXi Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, WuXi Biologics has a Total Debt of 640.51 M. This is 76.72% lower than that of the Healthcare sector and 97.21% higher than that of the Biotechnology industry. The total debt for all United States stocks is 87.95% higher than that of the company.
WuXi Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses WuXi Biologics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of WuXi Biologics could also be used in its relative valuation, which is a method of valuing WuXi Biologics by comparing valuation metrics of similar companies.WuXi Biologics is currently under evaluation in total debt category among its peers.
WuXi Fundamentals
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0551 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.31 % | |||
| Current Valuation | 29.3 B | |||
| Shares Outstanding | 2.11 B | |||
| Shares Owned By Institutions | 0.01 % | |||
| Price To Earning | 97.10 X | |||
| Price To Book | 6.03 X | |||
| Price To Sales | 2.03 X | |||
| Revenue | 10.29 B | |||
| Gross Profit | 4.83 B | |||
| EBITDA | 4.39 B | |||
| Net Income | 3.39 B | |||
| Cash And Equivalents | 9.86 B | |||
| Cash Per Share | 4.72 X | |||
| Total Debt | 640.51 M | |||
| Debt To Equity | 0.12 % | |||
| Current Ratio | 2.30 X | |||
| Book Value Per Share | 16.51 X | |||
| Cash Flow From Operations | 3.43 B | |||
| Earnings Per Share | 0.27 X | |||
| Price To Earnings To Growth | 0.81 X | |||
| Number Of Employees | 10.59 K | |||
| Beta | 1.09 | |||
| Market Capitalization | 34.7 B | |||
| Total Asset | 44.03 B | |||
| Z Score | 32.4 | |||
| Net Asset | 44.03 B |
About WuXi Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze WuXi Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of WuXi Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of WuXi Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for WuXi Pink Sheet Analysis
When running WuXi Biologics' price analysis, check to measure WuXi Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy WuXi Biologics is operating at the current time. Most of WuXi Biologics' value examination focuses on studying past and present price action to predict the probability of WuXi Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move WuXi Biologics' price. Additionally, you may evaluate how the addition of WuXi Biologics to your portfolios can decrease your overall portfolio volatility.